Search results
Results from the WOW.Com Content Network
His own research on chronic myelogenous leukemia (CML) has led the way to a new understanding of the disease. As Head of Hematology at the British Columbia Cancer Agency and the University of British Columbia for 18 years (1985–2003) he engineered the building of one of the first and largest bone marrow transplant programs in Canada. In ...
In 1987, Dynacare Health Group acquired its first diagnostic laboratory—Quality Medical Laboratories and established Dynacare Laboratories. [citation needed] By 2015, Dynacare was part of the Central Medical Laboratories (CML), established in 1959 in Winnipeg, Manitoba.
Dynacare is an operational partnership founded in 1997 as Gamma-Dynacare between: Dynacare Laboratories; Gamma North Peel Partnership Inc.; and Bio-Science Laboratory (Ontario) Limited. [ 2 ] [ 3 ] In 2002 Dynacare Laboratories (one of the Dynacare partners) was acquired by LabCorp for $480-million (U.S.) while also assuming Dynacare debt worth ...
Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a cancer of the white blood cells.It is a form of leukemia characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood.
In aCML many clinical features (splenomegaly, myeloid predominance in the bone marrow with some dysplastic features but without a differentiation block) and laboratory abnormalities (myeloid proliferation, low leukocyte alkaline phosphatase values) suggest the diagnosis of chronic myelogenous leukemia (CML).
The Tower space includes 150,000 sq ft (14,000 m 2) of "wet" laboratory bench space for Krembil basic science researchers. Krembil receives support from the Toronto General/Toronto Western Hospital Foundation which is currently embarked upon a $200 million "Brain Campaign" to support neuroscience research at Krembil. The campaign had raised ...
MaRS Discovery District is a not-for-profit corporation founded in Toronto, Ontario, Canada in 2000.Its stated goal is to commercialize publicly funded medical research and other technologies with the help of local private enterprises and as such is a public-private partnership. [1]
Brenda Jean Andrews CC FRSC is a Canadian academic, researcher and biologist specializing in systems biology and molecular genetics.. Andrews is known for her studies on cell cycle-regulated transcription and protein kinase function in yeast and for pioneering work with Charles Boone on genetic networks.